Literature DB >> 21742609

The glucocorticoid receptor and its expression in the anterior pituitary and the adrenal cortex: a source of variation in hypothalamic-pituitary-adrenal axis function; implications for pituitary and adrenal tumors.

George Briassoulis1, Svetozar Damjanovic, Paraskevi Xekouki, Hervé Lefebvre, Constantine A Stratakis.   

Abstract

OBJECTIVE: To review the expression of the glucocorticoid receptor (GR) in anterior pituitary and adrenocortical cells and tumors derived from these tissues as well as factors that may influence its expression.
METHODS: We present an overview of the relevant literature, with a focus on data generated from our studies.
RESULTS: The expression of the GR is an essential element of the negative feedback that closes the loop formed by corticotropin-releasing hormone, adrenocorticotropic hormone, and cortisol in the context of the hypothalamic-pituitary-adrenal (HPA) axis. Although the GR expression in anterior pituitary cells-and in particular the corticotrophs-was first demonstrated several years ago, it was not known until relatively recently where, by what cells, and in what form the GR is expressed in the adrenal cortex. The variability in the expression of the GR in pituitary and adrenocortical cells may underlie the substantial differences in HPA axis function across individuals, especially when testing for tumors associated with hypercortisolemia. This expression is influenced by a multitude of tissue-specific factors, which may explain why it is so difficult to interpret (or reproduce) studies that are based on GR functional polymorphisms on different cohorts of patients or even different sets of laboratory animals.
CONCLUSION: This review highlights the variability in expression and function of the GR in pituitary and adrenocortical cells as one of the reasons for the appreciable differences in HPA axis function across individuals. Particular attention was paid to interactions that may affect the interpretation of diagnostic testing of the HPA axis in patients with pituitary adenomas (Cushing disease) or adrenocortical tumors (Cushing syndrome).

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21742609      PMCID: PMC3652405          DOI: 10.4158/EP11061.RA

Source DB:  PubMed          Journal:  Endocr Pract        ISSN: 1530-891X            Impact factor:   3.443


  78 in total

1.  Cytoplasmic catalytic subunit of protein kinase A mediates cross-repression by NF-kappa B and the glucocorticoid receptor.

Authors:  V Doucas; Y Shi; S Miyamoto; A West; I Verma; R M Evans
Journal:  Proc Natl Acad Sci U S A       Date:  2000-10-24       Impact factor: 11.205

2.  ADRENAL RESPONSE TO INFUSED CORTICOTROPIN IN SUBJECTS RECEIVING GLUCOCORTICOIDS.

Authors:  J LANDON; V WYNN; V H JAMES; J B WOOD
Journal:  J Clin Endocrinol Metab       Date:  1965-05       Impact factor: 5.958

3.  The role of germline AIP, MEN1, PRKAR1A, CDKN1B and CDKN2C mutations in causing pituitary adenomas in a large cohort of children, adolescents, and patients with genetic syndromes.

Authors:  C A Stratakis; M A Tichomirowa; S Boikos; M F Azevedo; M Lodish; M Martari; S Verma; A F Daly; M Raygada; M F Keil; J Papademetriou; L Drori-Herishanu; A Horvath; K M Tsang; M Nesterova; S Franklin; J-F Vanbellinghen; V Bours; R Salvatori; A Beckers
Journal:  Clin Genet       Date:  2010-11       Impact factor: 4.438

4.  Normocortisolemic Cushing's syndrome initially presenting with increased glucocorticoid receptor numbers.

Authors:  R S Newfield; G Kalaitzoglou; T Licholai; D Chilton; J Ashraf; E B Thompson; M I New
Journal:  J Clin Endocrinol Metab       Date:  2000-01       Impact factor: 5.958

5.  Expression of glucocorticoid receptor isoforms in human adrenocortical adenomas.

Authors:  Belema Boyle; Henrietta Butz; Istvan Liko; Attila Zalatnai; Miklos Toth; Karolina Feldman; Janos Horanyi; Peter Igaz; Karoly Racz; Attila Patocs
Journal:  Steroids       Date:  2010-06-01       Impact factor: 2.668

6.  Clinical, hormonal and molecular characterization of pituitary ACTH adenomas without (silent corticotroph adenomas) and with Cushing's disease.

Authors:  Gérald Raverot; Anne Wierinckx; Emmanuel Jouanneau; Carole Auger; Françoise Borson-Chazot; Joël Lachuer; Michel Pugeat; Jacqueline Trouillas
Journal:  Eur J Endocrinol       Date:  2010-04-12       Impact factor: 6.664

Review 7.  Clinical, genetic and molecular characterization of patients with familial isolated pituitary adenomas (FIPA).

Authors:  Harvinder S Chahal; J Paul Chapple; Lawrence A Frohman; Ashley B Grossman; Márta Korbonits
Journal:  Trends Endocrinol Metab       Date:  2010-06-01       Impact factor: 12.015

8.  Molecular genetics of the aip gene in familial pituitary tumorigenesis.

Authors:  Asil Tahir; Harvinder S Chahal; Márta Korbonits
Journal:  Prog Brain Res       Date:  2010       Impact factor: 2.453

9.  Mutations of the gene encoding the protein kinase A type I-alpha regulatory subunit in patients with the Carney complex.

Authors:  L S Kirschner; J A Carney; S D Pack; S E Taymans; C Giatzakis; Y S Cho; Y S Cho-Chung; C A Stratakis
Journal:  Nat Genet       Date:  2000-09       Impact factor: 38.330

10.  Familial glucocorticoid receptor haploinsufficiency by non-sense mediated mRNA decay, adrenal hyperplasia and apparent mineralocorticoid excess.

Authors:  Jérôme Bouligand; Brigitte Delemer; Annie-Claude Hecart; Geri Meduri; Say Viengchareun; Larbi Amazit; Séverine Trabado; Bruno Fève; Anne Guiochon-Mantel; Jacques Young; Marc Lombès
Journal:  PLoS One       Date:  2010-10-22       Impact factor: 3.240

View more
  14 in total

1.  Celecoxib reduces glucocorticoids in vitro and in a mouse model with adrenocortical hyperplasia.

Authors:  Sisi Liu; Emmanouil Saloustros; Annabel Berthon; Matthew F Starost; Isabelle Sahut-Barnola; Paraskevi Salpea; Eva Szarek; Fabio R Faucz; Antoine Martinez; Constantine A Stratakis
Journal:  Endocr Relat Cancer       Date:  2015-10-05       Impact factor: 5.678

2.  Modeling the Sex Differences and Interindividual Variability in the Activity of the Hypothalamic-Pituitary-Adrenal Axis.

Authors:  Rohit T Rao; Ioannis P Androulakis
Journal:  Endocrinology       Date:  2017-11-01       Impact factor: 4.736

Review 3.  Glucocorticoids and the regulation of growth hormone secretion.

Authors:  Gherardo Mazziotti; Andrea Giustina
Journal:  Nat Rev Endocrinol       Date:  2013-02-05       Impact factor: 43.330

Review 4.  Skin manifestations of Cushing's syndrome.

Authors:  Constantine A Stratakis
Journal:  Rev Endocr Metab Disord       Date:  2016-09       Impact factor: 6.514

5.  Pregnane glycosides interfere with steroidogenic enzymes to down-regulate corticosteroid production in human adrenocortical H295R cells.

Authors:  Slavko Komarnytsky; Debora Esposito; Alexander Poulev; Ilya Raskin
Journal:  J Cell Physiol       Date:  2013-05       Impact factor: 6.384

6.  Dynamic responses of the adrenal steroidogenic regulatory network.

Authors:  Francesca Spiga; Eder Zavala; Jamie J Walker; Zidong Zhao; John R Terry; Stafford L Lightman
Journal:  Proc Natl Acad Sci U S A       Date:  2017-07-17       Impact factor: 11.205

7.  Low SGK1 expression in human adrenocortical tumors is associated with ACTH-independent glucocorticoid secretion and poor prognosis.

Authors:  Cristina L Ronchi; Silviu Sbiera; Ellen Leich; Frédérique Tissier; Sonja Steinhauer; Timo Deutschbein; Martin Fassnacht; Bruno Allolio
Journal:  J Clin Endocrinol Metab       Date:  2012-10-09       Impact factor: 5.958

8.  Pediatric Cushing's Disease and Pituitary Incidentaloma: Is This a Real Challenge?

Authors:  Rosa Maria Paragliola; Pietro Locantore; Alfredo Pontecorvi; Salvatore Maria Corsello
Journal:  Case Rep Endocrinol       Date:  2014-10-20

9.  Rapid intra-adrenal feedback regulation of glucocorticoid synthesis.

Authors:  J J Walker; F Spiga; R Gupta; Z Zhao; S L Lightman; J R Terry
Journal:  J R Soc Interface       Date:  2015-01-06       Impact factor: 4.118

Review 10.  Role of glucocorticoid negative feedback in the regulation of HPA axis pulsatility.

Authors:  Julia K Gjerstad; Stafford L Lightman; Francesca Spiga
Journal:  Stress       Date:  2018-05-15       Impact factor: 3.493

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.